The following texts have been used as reference sources for the compilation of The Renal Drug Database: Administration: Information is given on reconstitution, route and rate of administration, and other relevant factors. Much of the information relates to local practice, including information on the minimum volume that drugs can be added to. Only the most commonly used and compatible reconstitution and dilution solutions are stated. The product literature should always be consulted for the most up to date information. Dose in normal renal function: The doses quoted for patients with normal renal function are generally the licensed dosage recommendations stated in the Summary of Product Characteristics for each drug. Where a product is not licensed in the UK, dosage guidelines are provided by the relevant drug company.

Pityriasis versicolor: 50mg once daily for two to four weeks or 300mg to 400mg once weekly for one to three weeks. At the time of writing, there is little clinical experience with terbinafine in pregnant women, although data collected so far appear to suggest no increased risk for major malformations. Foetal toxicity and fertility studies in animals do not suggest any adverse effects. No evidence of impaired fertility or foetal harm was seen in pregnant rats and rabbits with oral doses up to 12 and 9 times the maximum recommended human dose respectively. The molecular weight is low enough that transfer to the embryo should be expected, but no studies evaluating the placental transfer of terbinafine in humans have been located.Although the effects on the breastfeeding infant are unknown, the safe use of fluconazole in infants has been documented. Side Effects Children have a higher fluconazole clearance than observed for adults. A dose of 100mg, 200mg and 400mg in adults corresponds to a 3mg/kg, 6mg/kg and 12mg/kg dose in children, respectively. Full access to over 800 drug monographs that comprise concise information on clinical use, dosing, important drug interactions, metabolism and drug administration.

The following details the structure of the monographs found within The Renal Drug Database. Where appropriate, supporting information is provided. Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. Accessed on 03 June 2015.Summary of Product Characteristics: Azocan 200mg capsules. FDC International Ltd. Revised June 2016. The manufacturer advises that mothers should not receive this treatment whilst breastfeeding. Briggs suggests due to the prolonged nature of the therapy, the potential for serious toxicity in a nursing infant may be increased.

Pharmaceutical Preformulation and Formulation: a Practical Guide from Candidate Drug Selection to Commercial Dosage Form - 2nd ed. (2009) Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London. The BNF is rarely used as a sole information source for managing medicines in renal impairment. Renal Drug Handbook and Renal Drug Database Hepatotoxicity (including fatalities) has been observed during treatment but the abnormalities have usually been reversible on discontinuation of fluconazole. Patients who develop abnormal liver tests should be monitored for the development of more serious hepatic injury. Discontinue treatment if clinical signs or symptoms consistent with liver disease develop during treatment.

The ultimate prescribing guide for renal practitioners

In fluorometric assays, spironolactone may interfere with the estimation of compounds with similar fluorescence characteristics. Overdosage Many of these problems can be avoided by careful choice and use of drugs. The Renal Drug Database seeks to assist healthcare professionals in this process. Advise patient on contraception required. If appropriate, advise patient to consider sperm cyropreservation. The Renal Drug Handbook. Fourth Edition (2014) ed. Ashley, C and Dunleavy, A, Radcliffe Publishing Ltd, London.